




NiCCC SGCTG - NSGO



Trial setting: tumour type/stage

Progressive or recurrent ovarian and endometrial
CCC within 6 months of previous platinum

Study Design:

Open Label Randomised Phase II Study

Sponsor:

NHS Greater Glasgow & Clyde

Planned No. of patients:

90 Ovarian and up to 30 endometrial

Current accrual:

32

Other important information:

Open Sites: UK: 16, France: 16

Additional Participating Countries:

The Netherlands, Denmark, Spain, Portugal,
Italy, Belgium still to open



Trial Design

90 pts with progressive or relapsed CCC of ovary within 6 months of previous platinum.

Plus up to 30 women with endometrial CCC

R
A
N
D
O
M
I
S
E

Control Arm: Chemotherapy

Ovary:

- PLD (40mg/m² day 1q28)
- Weekly Paclitaxel (80mg/m² day 1, 8, 15 q28)
- Weekly Topotecan IV (4mg/m² day 1, 8, 15 q28)

Endometrium:

- Carboplatin (AUC 5) /Paclitaxel 175 mg/m² q21
- Doxorubicin 60mg/m² q21

Experimental Arm: Nintedanib

Nintedanib 200mg bd until progression

Primary Endpoint: PFS

Secondary Endpoints: OS, Toxicity, RR, QoL, Q-Twist

